[TSH-receptor antibodies in thyroid diseases]

Area of Science:

• Endocrinology
• Immunology
• Clinical Diagnostics

Background:

• Thyroid disorders require accurate diagnostic tools.
• Distinguishing Graves' disease from other thyroid conditions is clinically important.
• Monitoring treatment efficacy is crucial for patient management.

Purpose of the Study:

• To evaluate the clinical utility of TSH receptor antibodies (TRAb) assay in diagnosing thyroid disorders.
• To compare the diagnostic and monitoring capabilities of TRAb assay versus thyroperoxidase antibodies (TPO-Ab) estimation.
• To assess the changes in TRAb and TPO-Ab levels during and after treatment for Graves' disease.

Main Methods:

• Assessed 313 patients with various thyroid diseases and 50 controls.
• Measured TSH receptor antibodies (TRAb) using the TRAK-assay.
• Measured thyroperoxidase antibodies (TPO-Ab) using the DYNOtest antiTPO assay.

Main Results:

• TRAb detected in 94.1% of Graves' disease patients, significantly higher than in other groups.
• TPO-Ab were elevated in Graves' disease and Hashimoto thyroiditis but showed less dynamic changes during treatment.
• TRAb levels decreased significantly after treatment for Graves' disease, indicating better treatment monitoring.
• TPO-Ab levels remained elevated post-treatment and post-thyroidectomy, with slow decline over many years.

Conclusions:

• TRAb estimation is a powerful tool for the differential diagnosis of Graves' disease.
• TRAb assay provides superior monitoring of treatment response in Graves' disease compared to TPO-Ab estimation.
• The findings support the routine use of TRAb assays for improved clinical management of thyroid disorders.